Company profile: Microvascular Tissues
1.1 - Company Overview
Company description
- Provider of biological vascular tissues for implantation, including mVASC Microvascular Tissue, a sterile, off-the-shelf human microvascular tissue graft designed to restore blood flow and support natural healing in damaged tissues.
Products and services
- Biological Vascular Tissue Engineering for Implantation: Develops biological vascular tissues for implantation, emphasizing human microvascular constructs that restore blood flow and support natural healing in damaged tissues, implantation-focused
- MVASC Microvascular Tissue: A sterile, off-the-shelf human microvascular tissue graft engineered to restore blood flow and support natural healing processes within damaged tissues, implantable
- Off-the-shelf Human Microvascular Graft Availability: Supplies off-the-shelf human microvascular tissue grafts enabling restoration of blood flow and natural healing in damaged tissues, sterile
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Microvascular Tissues
Cequent Pharmaceuticals
HQ: United States
Website
- Description: Provider of TransKingdom RNA interference (tkRNAi) therapeutics using non-pathogenic bacteria to deliver RNAi into cells to silence disease-causing genes, with pre-clinical drug candidates for colon cancer prevention and inflammatory bowel disease, targeting a wide range of human diseases from inflammatory conditions to cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cequent Pharmaceuticals company profile →
United Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology products and patient support services, including an Expanded Access Program for investigational drugs; ASSIST Access Solutions for medicine access and financial assistance; Archways educational resources for patients on inhaled or oral treprostinil via phone or video; and MyOldMeds.com for secure storage and disposal of unwanted or expired medications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full United Therapeutics company profile →
GSK
HQ: United Kingdom
Website
- Description: Provider of pharmaceutical medicines, vaccines, and consumer healthcare products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GSK company profile →
TesoRx
HQ: United States
Website
- Description: Provider of virtual pharmaceutical development and commercialization, offering TSX-049, an oral testosterone undecanoate for male hypogonadism with once-daily dosing without a high-fat meal; a neoliposomal drug delivery platform enhancing bioavailability via GI lymphatic absorption; licensing and joint development agreements; and clinical trials evaluating TSX-049, with anticipation of FDA approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TesoRx company profile →
AstraZeneca
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical research, development, manufacturing, and marketing of prescription medicines across oncology; cardiovascular, renal and metabolism; respiratory and immunology; vaccines and immune therapies; and rare diseases. Portfolio includes therapies such as datopotamab deruxtecan for advanced nonsquamous non-small cell lung cancer, with clinical trial survival benefits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AstraZeneca company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Microvascular Tissues
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Microvascular Tissues
2.2 - Growth funds investing in similar companies to Microvascular Tissues
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Microvascular Tissues
4.2 - Public trading comparable groups for Microvascular Tissues
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →